Oncology and X-Ray products company
Varian Medical Systems
) recently revealed that it was raising the profile of the
Calypso System as a mechanism for medical practitioners to
curtail the risk of heart ailments developed by women after many
years following therapy for breast cancer.
The Calypso System uses a set of small transmitting devices
that are placed on the patient's thoracic cavity and then
monitored during a therapy session. The technician starts the
therapy only when the transmitting devices reveal that the heart
is not coming in the way of a beam.
Besides the Calypso System, Varian maintains other tools to
reduce the risk of heart ailments for women receiving
radiotherapy. These include special beam configuring tools that
continually reshape the therapy beam so that it is in congruence
with the measurements of the targeted
Varian is a leading manufacturer of integrated radiotherapy
systems for cancer treatment, and a premier supplier of X-Ray
tubes for diagnostic imaging applications. The company operates
in a technology-driven environment where success depends on the
use of new technology, product development and upgrades. In the
radiation oncology market, Varian competes with
The company is poised to increase its market share in
radiation oncology. It currently enjoys a healthy demand for its
coveted TrueBeam technology, which has meaningfully contributed
to its net order oncology growth. Varian's TrueBeam is designed
to treat tumors with beams of high speed and precision. It
incorporates several technological innovations such as patient
positioning and managing his/her motion. Given its high intensity
nature, TrueBeam can dispense strong dosage over twice as fast as
that possible with earlier equipment.
Moreover, Varian continues to post decent results despite the
contagion of economic problems in Europe and sustained softness
in certain end markets. It enjoys a strong balance sheet marked
by low debt and sizeable cash. The company also periodically
deploys capital to boost investor confidence via share
However, Varian competes with larger players in a
technology-intensive industry. Further, uncertainties stemming
from health care reform and a still weak hospital capital
spending environment across many developed countries, especially
in Europe, are significant challenges.
The stock carries a Zacks Rank #3 (Hold).
Given Imaging Ltd.
) are Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) stocks,
respectively, which are expected to do well.
ACCURAY INC (ARAY): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
GIVEN IMAGING (GIVN): Free Stock Analysis
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.